Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Zevra Therapeutics Q2 2024 GAAP EPS $(0.48) Misses $(0.44) Estimate, Sales $4.449M Beat $4.412M Estimate

Author: Benzinga Newsdesk | August 13, 2024 04:12pm
Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.44) by 9.09 percent. This is a 500 percent decrease over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $4.449 million which beat the analyst consensus estimate of $4.412 million by 0.85 percent. This is a 47.47 percent decrease over sales of $8.470 million the same period last year.

Posted In: ZVRA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist